FDA Inspections
FDA BIMO (Clinical Investigation) Inspection
FDA's Bioresearch Monitoring (BIMO) program inspects the people and organizations behind a device clinical investigation. It is separate from the device quality system program and asks a different question: was the study run according to the regulations and the protocol, with subjects protected and data you can trust?
At a Glance
- Conducted by
- FDA investigators under the Bioresearch Monitoring program
- Who is inspected
- Sponsors, monitors and CROs, clinical investigators and IRBs
- Regulations
- 21 CFR Part 812, with Parts 50 (informed consent) and 56 (IRBs)
- Possible outcome
- Observations on Form 483; NAI, VAI or OAI classification
What It Is
Device clinical investigations run under 21 CFR Part 812, the investigational device exemption regulation, together with FDA's rules on informed consent (Part 50) and institutional review boards (Part 56). BIMO inspections check that these requirements were met and that the data submitted to FDA reflects what actually happened in the study.
BIMO is not a QMS inspection. The investigator isn't sampling process validations or supplier files. They are looking at protocol compliance, informed consent, device accountability, adverse effect reporting, monitoring, and the case report forms and source documents behind your data.
An inspection can be tied to a marketing application that relies on clinical data, can take place while a study is running, or can follow a complaint about how a study is being conducted.
Who Conducts It
FDA investigators working under the Bioresearch Monitoring program conduct these inspections. Depending on the study, they may visit the sponsor, a contract research organization handling monitoring, one or more clinical investigator sites, or the IRB that oversaw the study.
For a sponsor, several teams have a role: clinical operations for monitoring and study conduct, regulatory for IDE correspondence and reports, and quality for device accountability and the controls on the systems that hold study records.
What Triggers It
- A marketing submission that relies on clinical data from a device study
- An ongoing significant risk device study under an IDE
- Complaints or reports about how a study is being run, including concerns about subject protection
- Questions arising from FDA's review of study data about particular sites or results
What They Look At
Sponsor Responsibilities
Investigator selection and agreements, IRB approval, monitoring, required reports, and how the sponsor handled investigators who weren't complying.
Monitoring and CRO Oversight
Whether monitoring happened as planned, whether findings were escalated and resolved, and how the sponsor oversaw any CRO it used.
Informed Consent
Consent obtained before participation, on the IRB-approved version, and properly documented for every subject.
Protocol Compliance and Deviations
Whether subjects met eligibility criteria, procedures followed the protocol, and deviations were recorded, assessed and reported.
Device Accountability
Records of investigational devices shipped, received, used, returned or disposed of, reconciled by site.
Adverse Effect Reporting
Whether unanticipated adverse device effects were evaluated and reported as Part 812 requires.
Data Integrity
Whether case report forms and submitted data match source documents, and whether electronic systems holding study data are controlled.
IRB Oversight
For IRBs, membership, review procedures, continuing review and the records behind each decision.
How to Prepare
- 01
Reconcile Submission Data With Source
Sample subjects at each site and trace the data in your submission back to source documents.
- 02
Complete Device Accountability
Reconcile investigational device records across sponsor and sites so every unit is accounted for.
- 03
Organize the Study File
Make protocols and amendments, IRB approvals, consent versions, monitoring reports, deviations and correspondence easy to retrieve by site and date.
- 04
Resolve Open Monitoring Findings
Close or document open action items from monitoring visits, and show how serious issues were escalated.
- 05
Support Your Clinical Sites
Let investigator sites know an inspection may come, and help them organize their records without altering them.
- 06
Brief the Right People
Clinical operations, the medical monitor and regulatory staff should be ready to explain decisions made during the study.
Common Pitfalls
- Consent forms signed on the wrong version or after a study procedure had begun.
- Device accountability logs that don't reconcile between sponsor and sites.
- Monitoring reports that note the same issue visit after visit with no escalation.
- Protocol deviations recorded at the site but never assessed or reported by the sponsor.
- Submission data that can't be traced cleanly to source documents.
- Late edits to study records shortly before an inspection with no audit trail explaining them.
How QMSAdvisor Helps
- An AI-assisted first pass over your study documents (protocols, consent versions, monitoring reports and device accountability records), with every finding reviewed by an advisor.
- Advisor-reviewed findings that cite the document and location, so clinical and quality teams can resolve gaps site by site.
- An action plan that tracks open monitoring issues, accountability gaps and deviation assessments to closure with evidence.
- Inspection rehearsal for sponsor teams, focused on explaining decisions made during the study and the records behind them.
BIMO (Clinical) Inspection Readiness
Readiness for FDA bioresearch monitoring inspections of device clinical studies: sponsors, CROs and sites.
Submission Readiness (510(k), De Novo, PMA, Pre-Sub, 513(g))
The design, risk and V&V evidence behind a 510(k), De Novo or PMA, organized and gap-checked.
AI-Assisted QMS Gap Assessment
An AI-assisted first pass over the QMS documents you already have, with every result reviewed by an advisor.
Standards and Regulations Involved
Questions About the FDA BIMO (Clinical Investigation) Inspection
Is a BIMO inspection the same as a QMS inspection?
No. BIMO looks at clinical investigation conduct under Part 812 and related rules, while QMS inspections look at the quality system under the QMSR. Some sponsors face both, but the questions, records and people involved are different.
Who does FDA inspect under BIMO?
It can be the sponsor, a monitor or CRO, a clinical investigator or an IRB. Which party is inspected depends on the study and what FDA wants to verify.
Can a sponsor be responsible for problems at a clinical site?
Sponsors are responsible for selecting qualified investigators, monitoring the study and securing compliance when a site falls short. If monitoring found problems and nothing was done, that becomes a sponsor issue.
How should we prepare if the study is still running?
Treat inspection readiness as part of study conduct: keep the study file current, resolve monitoring findings as they arise and reconcile device accountability routinely. That's far easier than reconstructing records later.
Related Audits and Inspections
FDA PMA Pre-Approval Inspection
An FDA inspection tied to a PMA application that checks your quality system and its match to the submission.
Mock Audit and Mock Inspection
A realistic practice inspection, with an advisor playing the FDA investigator, before the real one arrives.
Remote and Hybrid Audits
Audits and regulatory assessments run partly or fully through video, screen sharing and electronic records.
Request an Assessment
Prepare for Your FDA BIMO (Clinical Investigation) Inspection With an Advisor
Tell us what's coming and when, and an advisor will scope readiness work around it. Please don't send confidential documents yet: secure upload is set up after onboarding.
